In a second major deal within three months for the Oxford University, UK, biotech spinout Evox Therapeutics, the company today announced a research collaboration and license agreement with Eli Lilly to leverage Evox’ proprietary DeliverEX platform. 9 June 2020
The US District Court for the District of New Jersey has ruled in favor of the Israel-based generics giant Teva in a patent infringement lawsuit regarding a generic version of Narcan (naloxone HCl) nasal spray for the treatment of opioid overdose. 8 June 2020
Belgium’s largest drugmaker UCB today announced the acquisition of Engage Therapeutics, a New Jersey, USA-based clinical-stage pharmaceutical company developing Staccato alprazolam for the rapid termination of an active epileptic seizure. 5 June 2020
Life sciences venture capital firm Forbion says that its newest portfolio company, Prilenia Therapeutics, a Naarden, Netherlands- and Herzliya, Israel-based clinical stage biotech company, has raised $62.5 million in a Series A financing round. 4 June 2020
Shares of Cambridge, UK-based Acacia Pharma were up 7.4% at 3.21 euros by mid-morning today, after it announced an amendment to the terms of its loan agreement with Italy’s Cosmo Pharmaceuticals. 1 June 2020
US pharma major Bristol Myers Squibb has announced that the European Commission (EC) has approved Zeposia (ozanimod) for the treatment of adult patients with relapsing remitting multiple sclerosis (RRMS) with active disease as defined by clinical or imaging features. 27 May 2020
Japanese drugmaker Shionogi said today that, at a meeting of the board of directors held on May 25, it was resolved to take up an option to acquire all the shares of US biotech firm Tetra Therapeutics. 26 May 2020
Based in Barcelona, Spain, Accure Therapeutics, a new pharma R&D player in the central nervous system (CNS) field, announces its launch with a Series A round of funding totaling 7.6 million euros ($8.1 million). 26 May 2020
In a U-turn by the US regulator, the Food and Drug Administration on Thursday approved Kynmobi (apomorphine HCI) sublingual film (APL-130277) for the acute, intermittent treatment of OFF episodes in patients with Parkinson’s disease (PD). 22 May 2020
Roche data from two pivotal Phase III open-label extension studies shows satralizumab was well-tolerated as a monotherapy or in combination with baseline immunosuppressive therapy in neuromyelitis optica spectrum disorder (NMOSD). 22 May 2020
Belgium-headquartered SERB Specialty Pharmaceuticals has made its first acquisition in the UK, thus substantially increasing its presence in this market. 20 May 2020
Teva Pharmaceutical Industries today announced that the China National Medical Products Administration (NMPA) has granted priority review approval for Austedo (deutetrabenazine tablets). 18 May 2020
California-based neurology specialist Neurocrine Biosciences has exercised its option to license the global rights of Swiss biotech Idorsia's ACT-709478. 12 May 2020
Swedish drug developer Orexo saw its shares jump 13% to 79.00 Swedish kronor by early afternoon, after it revealed the acquisition of exclusive US rights to Germany-based GAIA´s deprexis, a digital therapy to help patients manage their symptoms of depression and one of the most researched digital therapies in the world. 11 May 2020
Shares of Dr Reddy’s Laboratories rose more than 2% to 3,936.35 rupees, after the Indian drugmaker announced approval of Elyxyb (celecoxib oral solution 25mg/mL) by the US Food and Drug Administration). 7 May 2020
Newron Pharmaceuticals’ shares plummeted more than 68% to 1.98 Swiss francs by early afternoon trading, after it said it was abandoning development of its Rett syndrome candidate. 4 May 2020
There was a time when executives at Teva Pharmaceutical Industries thought that their product might be the third anti-calcitonin gene-related peptide (CGRP) drug to be recommended by the National Institute for Health and Care Excellence (NICE). 29 April 2020
UK-based Almac Discovery has announced a research tie-up with US pharma giant Merck & Co focusing on the generation of new small molecule inhibitors against specified deubiquitinase (DUB) targets for a range of neurodegenerative and other diseases. 29 April 2020
Today, the US Food and Drug Administration approved Miplyffa (arimoclomol), an oral medication for the treatment of Neimann-Pick disease, type C (NPC). 20 September 2024
US neuroscience company BioXcel Therapeutics has announced a new clinical prioritization and an update on its late-stage development programs for the treatment of agitation with BXCL501. 20 September 2024
Stalicla, a privately-held Swiss biotech, today announced that Dr Paulo Fontoura will be joining its drug development team as chief scientific and clinical development advisor. 19 September 2024
US clinical stage CNS drug developer Athira Pharma is taking decisive action following the company’s announcement of disappointing data from the Phase II/III LIFT-AD clinical trial of fosgonimeton to treat Alzheimer’s disease (AD). 18 September 2024
The US Food and Drug Administration (FDA) has approved Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) for the treatment of relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS), from Swiss pharma giant Roche. 16 September 2024
US pharma major Eli Lilly has announced a $1 billion expansion of its manufacturing site in Limerick, Ireland, to increase production of biologic active ingredients, including those for its recently approved treatment for early symptomatic Alzheimer's disease. 13 September 2024
US neurological diseases specialist Ovid Therapeutics has announced the promotion of Meg Alexander to president and chief operating officer (COO). 12 September 2024
The global migraine market in mature economies is projected to grow from $9.2 billion in 2023 to $16.4 billion by 2033, according to a report from GlobalData. 10 September 2024
Cartesian Therapeutics today announced that the US Food and Drug Administration (FDA) has granted Rare Pediatric Disease designation to Descartes-08 for the treatment of juvenile dermatomyositis (JDM). 9 September 2024
California’s Lykos Therapeutics is still trying to regroup after being rocked by the US Food and Drug Administration’s (FDA) rejection of midomafetamine (MDMA) capsules for the treatment of post-traumatic stress disorder (PTSD). 6 September 2024
The cost of prescribed dependency-forming medicines has decreased by £410 million ($539.6 million) since 2015/16, according to newly released data from the UK’s National Health Service (NHS). 6 September 2024
Shares in US biopharma Axsome Therapeutics, a biopharmaceutical company developing and delivering novel therapies for the management of CNS disorders, closed 7% higher on Wednesday. 5 September 2024
Mid-Atlantic BioTherapeutics (MABT) has announced a collaboration with Accelero Biostructures to identify novel inhibitors of USP30, a protein linked to neurological disorders and other conditions. 5 September 2024
Praxis Precision Medicines shared positive top-line results for its Phase II, proof of concept study evaluating relutrigine in SCN2A and SCN8A developmental and epileptic encephalopathy (DEE) patients. 4 September 2024